A proposed change to the new health insurance law that seeks to keep drug prices under lock and key has raised red flags.
This content was published on
2 minutes
Keystone-SDA/jdp
According to news agency Keystone-SDA, Adrian Lobsiger, the Federal Commissioner for Data Protection and Information, has written a letter criticising a confidentiality clause on the price of medicines in the proposed health insurance law.
He argues that the clauseExternal link contradicts the principle of public access. Lobsiger has already spoken out about his dissatisfaction with the provision and reiterated that it is essential that the public is able to check and monitor the price approval procedure for medicines.
Switzerland has been an advocate of price transparency. Last year, Swiss global health ambassador Nora Kronig told swissinfo.ch that “we are one of the only countries that are fully transparent about prices. There are no secret deals”.
Switzerland sets drug pricesExternal link based on a comparison to nine other countries and negotiations with individual manufacturers. But it is common knowledgeExternal link that many countries receive special discounts from companies on certain drugs. This means that the basket of prices Switzerland uses for comparison is wrong.
More
More
Government seeks to limit access to specialists to reduce healthcare costs
This content was published on
The government wants to restrict direct access for patients to specialist doctors to slow down a rise in costs for the Swiss health system.
In an effort to make innovative treatments particularly for cancer available more quickly, Switzerland also started to negotiate special rebate deals for medicines with pharmaceutical companies. Last year, public health authorities said there were deals on 20 or so treatments but this could rise with the introduction of gene therapies priced in the six to seven figures.
Although the information about the discount priceExternal link is available, some NGOs argue that it is difficult to find and calculate.
The law presented by Interior Minister Alain Berset earlier this week aims to create the legal basis for gaining access to innovative, costly medication through special deals or what are called pricing models. It suggests that in some cases the amount of the refund will not be made public in cases where the discount is so high that the company doesn’t wish to make it public.
The proposals are now available for consultation before it will be sent to parliament.
Popular Stories
More
Climate adaptation
Why Switzerland is among the ten fastest-warming countries in the world
Has your continent reached its peak or is there still potential for economic growth?
Some regions of the world are on an upward trajectory with the promise of a steadily improving future. Where do you live? And in which direction is your region or continent developing?
Switzerland must pay more than originally planned for US F-35 fighter jets
This content was published on
Switzerland has been unable to push through a fixed-price deal (CHF6 billion) with the United States for 36 new F-35 fighter jets.
This content was published on
A small two-seater plane crashed into Lake Geneva near Vevey on Tuesday afternoon. The two people on board were able to escape from the submerged aircraft without any injuries.
Swiss National Bank publishes new banknote designs
This content was published on
The Swiss National Bank (SNB) is working on a new series of banknotes on the theme of “Switzerland and its altitudes”. Twelve designs for the new series have been submitted and the public's opinion is now being sought.
US envoy meets Sudan army chief in Switzerland to discuss peace proposal
This content was published on
Sudan's army chief Abdel Fattah al-Burhan and US envoy for Africa Massad Boulos met in Switzerland to discuss a US peace plan aimed at ending the civil war in Sudan.
This content was published on
Late Shift [Heldin], a film by about overworked nurses, is Switzerland's candidate for the Best International Feature Film award at the Oscars next year.
US tariffs: most Swiss rule out making future concessions, survey reveals
This content was published on
According to a survey published on Wednesday, most Swiss residents are against offering concessions to the US in the current tariff dispute.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Push for drug pricing transparency strikes a nerve with industry
This content was published on
The 72nd World Health Assembly opens on Monday, but a draft resolution to end secrecy around drug pricing has already struck a nerve.
WHO adopts watered-down resolution on drug transparency
This content was published on
The World Health Organization (WHO) has adopted a resolution to improve transparency on drug prices but some people say it doesn't go far enough.
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.